Levothyroxine Sodium
NDC Package 70860-451-10
Package Information
Levothyroxine Sodium is levothyroxine is used to treat an underactive thyroid (hypothyroidism). Marketed by Athenex Pharmaceutical Division, Llc., this product is identified by NDC 70860-451 and is authorized under FDA application ANDA208749.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70860 - Athenex Pharmaceutical Division, Llc.
- 70860-451 - Levothyroxine Sodium
- 70860-451-10 - 1 VIAL in 1 CARTON / 5 mL in 1 VIAL
- 70860-451 - Levothyroxine Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70860-451-10 identifies a specific commercial package of 1 vial in 1 carton / 5 ml in 1 vial of Levothyroxine Sodium, labeled by Athenex Pharmaceutical Division, Llc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Athenex Pharmaceutical Division, Llc. on December 15, 2018. The current certification is valid through July 31, 2024.
What are the primary indications for this medication?
Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as certain types of goiters, thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.
How is this Athenex Pharmaceutical Division, Llc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70860045110. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
